Annual Statement of Changes in Beneficial Ownership (5)
31 Marzo 2021 - 10:09PM
Edgar (US Regulatory)
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ]
Form 3 Holdings Reported
[ ]
Form 4 Transactions Reported
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0362
Estimated average burden
hours per response...
1.0
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
CODE KENNETH REAY | 2. Issuer Name and Ticker or Trading SymbolBIOLARGO, INC. [BLGO] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Science Officer |
|
(Last)
(First)
(Middle)
14921 CHESTNUT ST. | 3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY)
5/4/2020 |
|
(Street)
WESTMINSTER, CA 92683
(City)
(State)
(Zip)
| 4. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form Filed by One Reporting Person
___ Form Filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any | 3. Trans. Code
(Instr. 8) | 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) | 7. Nature of Indirect Beneficial Ownership
(Instr. 4) |
| Amount | (A) or (D) | Price |
| Common Stock | 12/31/2020 | | A5 | 335840 | A | $0.12 (2) | 24443647 (4) | D (3) | |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year
(Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) | 11. Nature of Indirect Beneficial Ownership
(Instr. 4) |
| (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Option to Purchase Common Stock | $0.14 | 5/1/2020 | | A | 343571 | | 5/1/2020 | 5/1/2030 | Common stock | 343571 | $0 | 408571 (1)(4) | D | |
| Explanation of Responses: |
| (1) | The total reflects the March 1, 2020, expiration of an option to purchase 200,000 shares of the Issuer's common stock. |
| (2) | Shares received from Issuer in exchange for a reduction in amounts owed by Issuer to Reporting Person for salary and unreimbursed business expenses (equal to the product of the number of shares issued and the acquisition price per share). |
| (3) | Includes 22,139,012 shares owned indirectly by Reporting Person through a wholly owned corporation. |
| (4) | This total is as of the date of the filing of this Report. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
CODE KENNETH REAY
14921 CHESTNUT ST.
WESTMINSTER, CA 92683 | X | X | Chief Science Officer |
|
Signatures
|
| /s/ John R. Browning, Attorney-in-fact | | 3/31/2021 |
| **Signature of Reporting Person | Date |
Grafico Azioni BioLargo (QX) (USOTC:BLGO)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni BioLargo (QX) (USOTC:BLGO)
Storico
Da Gen 2024 a Gen 2025
